Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07623668
PHASE3

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

Sponsor: Oculis

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).

Official title: A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2026-05-28

Completion Date

2028-12

Last Updated

2026-08-14

Healthy Volunteers

No

Conditions

Interventions

DRUG

Privosegtor

Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days

DRUG

Methylprednisolone

Methylprednisolone 1 g/day IV for 5 treatment days

OTHER

Placebo

0.9% sodium chloride (NaCl) solution IV for 5 treatment days

Locations (4)

Kahana Oculoplastic and Orbital Surgery

Livonia, Michigan, United States

Medical University of South Carolina, Storm Eye Institute

Charleston, South Carolina, United States

UT Southwestern Medical Center (Ophthalmology CRU)

Dallas, Texas, United States

Neuro-Eye Clinical Trials

Houston, Texas, United States